A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

Eligibility Criteria

• * Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
• * Participants who are overtly healthy.
• * Male or female of non-childbearing potential.
• * Capable of giving signed informed consent.
• * History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
• * Abnormal blood pressure.
• * Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• * Breast cancer within the past 10 years.
• * Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
• * History of clinically relevant hepatitis within last 6 months.
• * Patients with chronic hepatitis B infection.
• * History of sensitivity to any of the study interventions, a history of drug allergy or other allergy that contraindicates their participation.
• * The participant has an underlying skin disease or disorder that would interfere with assessment of injection sites.
• * Participants considered to have insufficient musculature to allow safe VH4011499 intramuscular administration will be excluded.
• * History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition.
• * Any preexisting physical or mental condition which may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
• * Past or intended use over-the-counter or prescription medication (including herbal medications) within 7 days prior to dosing
• * Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
• * Current enrollment or recent past participation in another investigational study.
• * Positive HIV antibody/antigen test.
• * ALT more than or equal to (\>=)1.5x upper limit of normal (ULN), Total bilirubin \>=1.5x ULN (isolated total bilirubin more than (\>)1.5xULN), and/or estimated creatinine clearance (eGFR) of less than (\<)60 millilitre per minute (mL/min)/1.73 square meter (m\^2).
• * Regular use of tobacco or nicotine-containing products, regular alcohol consumption and/or use of known drugs of abuse.
• * QT interval corrected for heart rate according to Fridericia's formula (QTcF) \>450 msec.
• * Evidence of previous myocardial infarction, any conduction abnormality, any significant arrhythmia, non-sustained or sustained ventricular tachycardia, and/or sinus pauses (\>3 seconds).
• * The participant has a tattoo or other dermatological condition overlying the location of injection or a prior history of silicone implants or fillers which may interfere with interpretation of ISRs or administration of study product.